Abstract

Background: Type 2 diabetes, a chronic condition with insulin resistance and impaired glucose metabolism, often leads to obesity and dyslipidaemia. Traditional antidiabetic medications struggle with weight reduction and lipid profile improvement. Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors offer a unique therapeutic approach.
Objective: The study investigates the impact of SGLT-2 inhibitors on weight reduction and lipid profile improvement in type 2 diabetes patients, evaluating evidence from various patients.
Methods: A study involving 103 Libyan patients with type 2 diabetes mellitus evaluated the effects of SGLT-2 inhibitors on body weight and lipid profiles. The study compared two types of SGLT-2 inhibitors, Dapagliflozin (DAPA, 5-10mg/kg, n=69) and Empagliflozin (EMPA, 12.5mg/kg, n=34). Patients were categorized based on weight and age.
Result: The study found that treatment with SGLT-2 inhibitors significantly reduced body weight compared to placebo or other antidiabetic drugs, particularly for patients receiving both DAPA and EMPA. EMPA data shows that patients under 50 years old and weighing less than 90kg experienced the largest weight decrease among the groups. SGLT-2 inhibitors showed a 13% loss in DAPA impact and a pooled effect size of 17.95%. They also showed positive effects on lipid profiles, decreasing triglycerides and increasing high-density cholesterol.
Conclusion: SGLT-2 inhibitors significantly impact weight loss and fat reduction in type 2 diabetics, promising potential for disease alleviation. However, further research is needed to ensure safety and tolerability.

Keywords:Diabetes; SGLT-2 inhibitors; Body weight reduction; Lipid profile improvement